The novel <scp>PAR</scp>2 ligand <scp>C</scp>391 blocks multiple <scp>PAR</scp>2 signalling pathways <i>in vitro</i> and <i>in vivo</i>

Abstract

C391 is the first low MW antagonist to block both PAR2 Ca²⁺ and MAPK signalling pathways activated by peptidomimetics and/or proteinase activation. C391 represents a new molecular structure for PAR2 antagonism and can serve as a basis for further development for this important therapeutic target.